Latest Alzheimer's Stories
LA JOLLA, Calif., Oct. 2, 2012 /PRNewswire/ -- As Baby Boomers become senior citizens, Alzheimer's disease and other forms of dementia are on track to reach epidemic proportions, with a new diagnosis every 68 seconds and an annual cost of $1.2 trillion projected by 2050, not to mention the psychological toll on family members caring for their loved ones. UCTV Prime's YouTube original series "Heartache and Hope: America's Alzheimer's Epidemic" reveals what it's like for patients and...
SEOUL, South Korea, Sept. 26, 2012 /PRNewswire/ -- In the first study of its kind, researchers at Korea's leading university and the RNL Bio Stem Cell Technology Institute announced this week the results of a study that suggests an astounding possibility: adult stem cells may not only have a positive effect on those suffering from Alzheimer's disease, they can prevent the disease. Using fat-derived adult stem cells from humans [scientific term: adMSCs, or human, adipose-derived...
MANCHESTER, England, September 10, 2012 /PRNewswire/ -- Investigational drug study follows earlier study with promising results in mild to moderate Alzheimer's patients TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held...
KALAMAZOO, Mich., Sept. 7, 2012 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) will provide an update on the clinical evaluation of MSDC-0160, a first in class mTOT Modulator(TM) that is being investigated in an ongoing Phase 2a trial in subjects with mild to moderate dementia due to Alzheimer's disease. The update will be presented at the Alzheimer's Drug Discovery Foundation (ADDF) 13th International Conference on Alzheimer's Drug Discovery in Jersey City, NJ...
Recipients recognized for outstanding contributions to the fight against Alzheimer's disease WASHINGTON, Sept. 7, 2012 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the recipients of the first annual Research and Hope Awards. This year's award honors outstanding achievements in academia, the biopharmaceutical research sector, as well as the patient and caregiving communities to help advance medical progress and patient...
EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ -- The US Food and Drug Administration has approved a higher dose of Exelon(®) Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease. The new 13.3 mg/24 h dosage strength of Exelon Patch provides physicians with a new treatment option for patients who are experiencing a decline in overall function and cognition. "Alzheimer's disease is marked by progressive symptomatic...
GLEN ALLEN, Va., Aug. 23, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary Rock Creek Pharmaceuticals Inc., announced today that the Alzheimer's study of the company's dietary supplement Anatabloc(® )has screened and enrolled its first patient. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) The Alzheimer's study, entitled, "A Three Month, Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial...
VANCOUVER, British Columbia, July 18, 2012 /PRNewswire-USNewswire/ -- In April 2011, the U.S. National Institute on Aging (NIA) and the Alzheimer's Association published new criteria and guidelines for the diagnosis of Alzheimer's disease. These guidelines separate the progression of Alzheimer's into three phases: (1) pre-clinical (or pre-symptomatic) Alzheimer's disease, (2) mild cognitive impairment (MCI) due to Alzheimer's disease, and (3) Alzheimer's disease dementia. Phases (1)...
- Phase 2b study of a new symptomatic drug - - One-year extension trial of a medical food - - 9-month trial of a dietary supplement - - 18-month study of a home-based care coordination intervention - VANCOUVER, British Columbia, July 18, 2012 /PRNewswire-USNewswire/ -- Results from four clinical trials reported at the Alzheimer's Association International Conference® 2012 (AAIC® 2012) demonstrate the wide variety of approaches being pursued to improve memory, thinking, quality...
VANCOUVER, British Columbia, July 18, 2012 /PRNewswire-USNewswire/ -- New studies reported at the Alzheimer's Association International Conference 2012 (AAIC® 2012), July 14-19, in Vancouver cover the spectrum of Alzheimer's disease and dementia research, including causes, risk factors, detection and diagnosis, treatment, and prevention. The Alzheimer's Association International Conference is the premier annual forum for presentation and discussion of the latest Alzheimer's and dementia...
